Axiom Biotechnologies Inc. appoints director of business development and corporate communications.

SAN DIEGO--(BUSINESS WIRE)--Sept. 12, 1996--Management of privately-held Axiom Biotechnologies Inc. Thursday announced that the company has appointed James P. Linton, Ph.D. as its director of business development and corporate communications.

Linton will be responsible for establishing corporate partnerships, increasing AXIOM's technology awareness and raising capital as the company brings its drug discovery technology to the marketplace.

"We are very pleased to have Jim join our team. His unique blend of business experience and scientific training will permit us to move aggressively to expand the company's capital base and establish important strategic alliances," said Pandi Veerapandian, Ph.D., president and chief scientific officer.

Prior to joining Axiom, Linton worked as director of life science & technology at Stoorza, Ziegaus & Metzger Inc., where he headed the business development and investor relations activities for the biotechnology consulting team.

Previously, from 1990-1994, he served as manager of business development at Sequana Therapeutics and as manager of investor relations and collaborative program administration for Advanced Tissue Sciences.

During his tenure in biotechnology he has participated in raising more than $70 million in public and private financing and has established more than 20 corporate and research collaborations. Linton obtained a Ph.D. in molecular biology from Emory University in Atlanta, and a Masters of Business Administration in marketing from the University of California at Davis.

Axiom Biotechnologies is an emerging leader in the field of drug discovery. The company's proprietary CombiScreen and Cell Physiometer technology is a breakthrough in pharmacological screening technology that can evaluate combinatorial libraries on the natural target cells in a high throughput format.

AXIOM's proprietary molecular optimization program in conjunction with the above screening process will enable its corporate partners to improve the probability of identifying successful drug candidates and to accelerate the identification of effective lead compounds.

CONTACT: Axiom Biotechnologies Inc., San Diego

James Linton, 619/455-4500